Telangana: Aurobindo Pharma has announced that the Company will be investing Rs.10.40 crores to acquire 26 percent equity and ...

Aurobindo Pharma’s Q3 net profit declined 10% YoY to Rs 846 crore, despite record revenue of Rs 7,979 crore. US sales ...

Ahead of earnings announcement, shares of Aurobindo Pharma ended the trading session flat at ₹1,184.50 apiece on the BSE, ...

Aurobindo Pharma reported a 10% YoY decline in net profit to Rs 846 crore for Q3FY25, mainly due to a decrease in US sales.

Aurobindo Pharma on Thursday reported a 10 per cent year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the ...

Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in expenses more than offset strong demand for its generic drugs.

The Hyderabad-based bulk and generic drug maker's net profit fell 9.7% year-on-year to Rs 846 crore in the quarter ended Dec.

Hyderabad: Degrowth in its US formulations business dragged down Aurobindo Pharma's consolidated net profits for the third ...

Aurobindo Pharma's net profit fell 10% to Rs 846 crore in Q3 FY25, while revenue rose to Rs 7,979 crore. The company attributes this to volume growth and new launches.

Aurobindo Pharma's net profit declines 10% due to lower U.S. formulations revenue, but revenue from operations increases.

Quarterly Net Profit at Rs. 845.81 crore in December 2024 down 9.66% from Rs. 936.29 crore in December 2023. EBITDA stands at ...